IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
- Conditions
- Early-stage Breast Cancer
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 450
- Registration Number
- NCT05377684
- Locations
- 🇮🇹
Policlinico S. Orsola - Malpighi, Bologna, Italy
🇮🇹Ospedale Oncologico "A. Businco", Cagliari, Italy
🇮🇹Azienda Ospedaliero-Universitaria Careggi (AOUC), Firenze, Italy
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
- Conditions
- Advanced Renal Cell Carcinoma
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 311
- Registration Number
- NCT05361434
- Locations
- 🇧🇪
CHU St Pierre & Brugmann, Bruxelles, Belgium
🇧🇪Jessa Ziekenhuis, Hasselt, Belgium
🇧🇪CHU Namur Mont-Godinne, Yvoir, Belgium
Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.
- Conditions
- Post-Stroke Chronic Upper Limb Spasticity
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 121
- Registration Number
- NCT05224349
- Locations
- 🇩🇪
Nervenarztpraxis, Altdorf, Germany
🇩🇪Neurologisches Zentrum, Berlin, Germany
🇩🇪Neurozentrum Erding, Erding, Germany
Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
- Conditions
- Acromegaly
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Ipsen
- Registration Number
- NCT05184231
A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK).
- Conditions
- Upper Limb Spasticity (ULS)
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 16
- Registration Number
- NCT05169775
- Locations
- 🇬🇧
Hull University Teaching Hospital NHS Trust, Hull, United Kingdom
A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 66
- Registration Number
- NCT05029622
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, China
🇨🇳No.1 Hospital of Jilin University (Bethune first hospital of Jilin University), Changchun, China
🇨🇳Children's Hospital of Fudan University, Changhai, China
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
- Conditions
- Fibrodysplasia Ossificans Progressiva (FOP)
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 61
- Registration Number
- NCT05027802
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Children's Hospital of Philidelphia, Philadelphia, Pennsylvania, United States
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 45
- Registration Number
- NCT04970407
- Locations
- 🇬🇧
Mac Research Clinical research Unit, Manchester, United Kingdom
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
- Conditions
- Advanced Renal Cell Carcinoma (aRCC)
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 281
- Registration Number
- NCT04957160
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Royal Surrey County Hospital, Guildford, United Kingdom
🇬🇧Barts Cancer Institute, London, United Kingdom
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
- Conditions
- Upper Limb Spasticity
- Interventions
- Biological: AboBoNT-ABiological: OnaBoNT-A
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 464
- Registration Number
- NCT04936542
- Locations
- 🇨🇦
Victoria General Hospital, Victoria, Canada
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States